- Home
- PHAR vs BBNX Comparison
PHAR vs BBNX Comparison
Compare PHAR & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- BBNX
- Stock Information
- Founded
- PHAR 1988
- BBNX 2015
- Country
- PHAR Netherlands
- BBNX United States
- Employees
- PHAR N/A
- BBNX N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- PHAR Health Care
- BBNX Health Care
- Exchange
- PHAR Nasdaq
- BBNX Nasdaq
- Market Cap
- PHAR 951.7M
- BBNX 967.6M
- IPO Year
- PHAR N/A
- BBNX 2025
- Fundamental
- Price
- PHAR $14.34
- BBNX $23.22
- Analyst Decision
- PHAR Strong Buy
- BBNX Strong Buy
- Analyst Count
- PHAR 3
- BBNX 10
- Target Price
- PHAR $30.00
- BBNX $26.10
- AVG Volume (30 Days)
- PHAR 14.9K
- BBNX 1.0M
- Earning Date
- PHAR 10-23-2025
- BBNX 11-06-2025
- Dividend Yield
- PHAR N/A
- BBNX N/A
- EPS Growth
- PHAR N/A
- BBNX N/A
- EPS
- PHAR N/A
- BBNX N/A
- Revenue
- PHAR $339,836,000.00
- BBNX $78,022,000.00
- Revenue This Year
- PHAR $17.44
- BBNX $42.80
- Revenue Next Year
- PHAR $8.46
- BBNX $34.58
- P/E Ratio
- PHAR N/A
- BBNX N/A
- Revenue Growth
- PHAR 22.44
- BBNX 550.45
- 52 Week Low
- PHAR $7.31
- BBNX $8.89
- 52 Week High
- PHAR $17.08
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- PHAR 50.39
- BBNX 60.72
- Support Level
- PHAR $14.22
- BBNX $21.57
- Resistance Level
- PHAR $16.29
- BBNX $22.71
- Average True Range (ATR)
- PHAR 0.50
- BBNX 1.33
- MACD
- PHAR -0.13
- BBNX -0.07
- Stochastic Oscillator
- PHAR 37.30
- BBNX 88.16
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.